Earnings Play: Agilent Technologies
Jason Lubin November 20, 2020 11:10 AM
Upside breakout from a short-term falling wedge pattern.
On Monday, after market, Agilent Technologies (A) is anticipated to release fourth quarter EPS of $0.92 compared to $0.89 a year ago on revenue of approximately $1.4 billion, in line with last year. Agilent is an international life sciences and diagnostics company, and on November 13th, the Co announced that it received approval from the U.S. Food and Drug Administration (FDA) for the use of its PD-L1 IHC 22C3 pharmDx as a diagnostic aid in the identification of triple-negative breast cancer and other conditions.
Technically speaking, on a daily chart, Agilent's stock price has been in a strong uptrend since mid-March. Today, price opened above the upper trendline of a short-term falling wedge pattern that price has been declining within since November 9th, after the stock made a record high of 117.50. The simple moving averages (SMA) are set-up in a bullish manner, with the 20-day SMA above the 50-day SMA and the 50-day SMA above the 200-day SMA. The RSI is over 50 and pointing upwards. Price will likely advance towards its all-time high of 117.50. If price can breakout to the upside of 117.50, then its next target would be 132.75. If price retreats then investors should look for a rebound off of 100.50. If price breaks out below 100.50 it would be a bearish signal that could send price tumbling back to 93.00.
Source: GAIN Capital, TradingView
Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.
Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to Forex.com or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.